TPIP 12-Month Data Shows Sustained 6MWD Gain, 60% NT-proBNP Drop in PAH
INSM sits 23% above its 52-week low of $90.39.
Summary
Insmed's 12-month open-label extension data for TPIP in pulmonary arterial hypertension (PAH) showed durable efficacy and a clean safety profile. Patients continuing TPIP maintained a 55.7-meter improvement in 6-minute walk distance, while those crossing over from placebo caught up to 54.1 meters. NT-proBNP, a key biomarker of heart failure severity, dropped roughly 60% from baseline in both groups and held through Month 12. Functional class improvements were striking: about 80% of patients reached WHO Class I or II, with over 25% achieving Class I. The REVEAL Lite 2.0 risk score improved by 2.0 points in the continued group, and roughly 65% of patients hit Refined Low Risk status. Safety was consistent with prior data—treatment-emergent adverse events in 89% of patients, serious events in 18.7%, and four deaths deemed unrelated to treatment. This is the first detailed look at long-term TPIP outcomes and materially de-risks the program ahead of a potential regulatory filing. The data follows the 8-K filed this morning and supports TPIP's differentiation in a market with limited oral prostacyclin options.
At the time of this announcement, INSM was trading at $111.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.8B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.